Edition:
India

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

3.00USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$3.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
31,202
52-wk High
$6.85
52-wk Low
$2.78

Select another date:

Mon, Jan 8 2018

BRIEF-ProQR And Galapagos Announce Research Collaboration

* PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY

BRIEF-ProQR Receives Orphan Drug Designation From EMA For Drug Candidate Qr-313 For Dystrophic Epidermolysis Bullosa

* PROQR RECEIVES ORPHAN DRUG DESIGNATION FROM EMA FOR DRUG CANDIDATE QR-313 FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage:

BRIEF-Proqr reports loss of EUR 0.42 per share​

* Proqr Therapeutics Nv - ‍net result for three month period ended September 30, 2017 was a EUR 10.5 million loss or EUR 0.42 per share​ Source text for Eikon: Further company coverage:

BRIEF-ProQR doses first LCA 10 patient in clinical trial of QR-110

* ProQR doses first LCA 10 patient in clinical trial of qr-110, ProQR's lead program for genetic blindness

BRIEF-JDG B.V. reports 10.5 pct passive stake in ProQR Therapeutics NV as on Sept 14

* JDG B.V. Reports 10.5 percent passive stake in ProQR Therapeutics NV as on September 14 - SEC Filing‍​ Source text: (http://bit.ly/2yhtqSA) Further company coverage:

BRIEF-ProQR announces positive top-line results from a phase 1b study of QR-010

* ProQR announces positive top-line results from a Phase 1b study of QR-010 in subjects with Cystic Fibrosis

BRIEF-ProQR gets orphan drug designation from FDA for drug candidate QR-313

* ProQR receives orphan drug designation from FDA for drug candidate QR-313 for dystrophic epidermolysis bullosa and will present data at two scientific conferences

BRIEF-ProQR Therapeutics spins out Amylon Therapeutics

* ProQR therapeutics - spun out Amylon Therapeutics, a privately-held company focused on development of therapies for central nervous system disorders

BRIEF-ProQR Q2 loss per share EUR 0.47

* ProQR Therapeutics - enrollment completed in phase 1b clinical trial in cystic fibrosis (CF) and top-line data expected to be announced in September Source text for Eikon: Further company coverage:

Select another date: